studies

la/mBC - HR-positive - 1st line (L1), palbociclib plus endocrine therapy vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsPENELOPE-B, 2021 0.87 [0.61; 1.24] 0.87[0.61; 1.24]PENELOPE-B, 202110%1,250NAnot evaluable iDFSdetailed resultsPENELOPE-B, 2021 0.93 [0.74; 1.17] 0.93[0.74; 1.17]PENELOPE-B, 202110%1,250NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-10 08:20 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 352,354 - treatments: 1407